Jessica Desalvo, DO
Internal Medicine · Philadelphia, PANPI 1780970442
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 323 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 38 manufacturers reported payments, led by Gilead at 24.4% of the total. 2025 is the largest year on record at $1,402, 6.5 times the $217 reported in 2019. Among internal medicine clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 323 payments — averaging $16.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$1K
- AbbVie$1K
- Novo Nordisk$685
- Astellas Pharma US Inc$354
- Pfizer$293
- Shield Therapeutics Inc$164
- plus $1K from 32 others
What the payments were for
- Food & beverage$5,299100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$5,299 in reported general payments places this provider in the 90th percentile of 5,705 internal medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Rosuvastatin Calcium | 55 | $1,470 |
| Olmesartan Medoxomil | 27 | $524 |
| Levothyroxine Sodium | 49 | $474 |
| Atorvastatin Calcium | 60 | $427 |
| Ezetimibe | 11 | $362 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 17 | $283 |
| Lisinopril | 23 | $227 |
| Sildenafil Citrate | 13 | $209 |
| Amlodipine Besylate | 41 | $195 |
| Losartan Potassium | 15 | $165 |
| Metformin Hcl | 25 | $144 |
| Alendronate Sodium | 19 | $110 |
| Fluoxetine Hcl | 22 | $72 |
| Trazodone Hcl | 13 | $14 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Philadelphia
- Jonathan EpsteinPhiladelphia$13.1M
- Pitamber DevgonPhiladelphia$7.5M
- Daniel RaderPhiladelphia$1.7M
- David GoldmannPhiladelphia$525K
- Eyob FeyssaPhiladelphia$328K
- Emil AbramianPhiladelphia$199K
- Michael KnightPhiladelphia$178K
- James BlakePhiladelphia$164K
- Gina SimonciniPhiladelphia$158K
- James LewisPhiladelphia$106K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.